Literature DB >> 8834199

We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept.

W L Chiou1.   

Abstract

It is shown that the conventional method (based on the thin-wall membrane theory) of studying the rate of disappearance or absorption from the lumen alone may not yield the correct intestinal wall (membrane) permeability coefficient of drugs. Potential reasons for causing this problem such as first-pass metabolism and accumulation of drugs in gut wall or tissue as well as back diffusion of drugs from the gut tissue to the lumen (i.e., a part of exsorption phenomenon) and potential major transport barriers across the protoplasm, basal membrane, and basement membrane are discussed. Contrary to the conventional concept, basal and basement membranes should also be considered major barriers for absorption into the blood for compounds with low intestinal permeability, and the protoplasm or cytoplasma should also be considered a major absorption barrier for compounds with high intestinal permeability. Strictly speaking, the conventional experimental method cannot be considered a bona fide method for studying drug permeability that deals with the movement of drug molecules from one side to the other side of a membrane, cell, medium, or device. The wall permeability coefficient thus obtained may therefore not represent the true wall permeability coefficient. "Intestinal absorptive clearance per unit gross surface area" is advocated as the best alternative term because it should more accurately reflect the true meaning of an experimental result for any compounds studied. In contrast to conventional cylindrical, unstirred tube models for the determination of wall permeability coefficients, the absorptive clearance calculation can be made based on a physiologically more realistic model-independent, "flat" or "distended," stirred (not well-stirred) intestinal model. Two model-independent terms, "effective intestinal permeability coefficient" and "effective absorptive permeability coefficient," are recommended as the second alternatives. These terms are theoretically valid for compounds that are not metabolized in the intestinal tissue; they represent the overall permeability across the intestinal tissue (from lumen to blood) under given experimental conditions. Potential shortcomings of using dimensionless wall permeability in the conventional absorption modeling are also discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8834199     DOI: 10.1007/bf02354288

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  30 in total

1.  Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination.

Authors:  J H Kou; D Fleisher; G L Amidon
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

2.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

Authors:  P Artursson; J Karlsson
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

3.  The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats.

Authors:  W L Chiou
Journal:  Biopharm Drug Dispos       Date:  1995-01       Impact factor: 1.627

4.  A convective mass transfer model for determining intestinal wall permeabilities: laminar flow in a circular tube.

Authors:  R L Elliott; G L Amidon; E N Lightfoot
Journal:  J Theor Biol       Date:  1980-12-21       Impact factor: 2.691

5.  Physiological measurements of luminal stirring in the dog and human small bowel.

Authors:  M D Levitt; J K Furne; A Strocchi; B W Anderson; D G Levitt
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  Comparative drug exsorption in the perfused rat intestine.

Authors:  J D Huang
Journal:  J Pharm Pharmacol       Date:  1990-03       Impact factor: 3.765

7.  Influence of anesthetic regimens on intestinal absorption in rats.

Authors:  H Yuasa; K Matsuda; J Watanabe
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

8.  Intestinal absorption of (-)-carbovir in the rat.

Authors:  I Soria; C L Zimmerman
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

9.  First-pass accumulation of salicylic acid in gut tissue after absorption in anesthetized rat.

Authors:  Y M Choi; S M Chung; W L Chiou
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

10.  Intestinal absorption of several beta-lactam antibiotics. II. Absorption characteristics of amino-penicillins and amino-cephalosporins.

Authors:  K Umeniwa; O Ogino; K Miyazaki; T Arita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1979-09       Impact factor: 1.645

View more
  6 in total

1.  The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology.

Authors:  W L Chiou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

2.  Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.

Authors:  S M Chung; E J Park; S M Swanson; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

3.  New perspectives on the theory of permeability and resistance in the study of drug transport and absorption.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

4.  Comparison of oral absorption and bioavailablity of drugs between monkey and human.

Authors:  Win L Chiou; Paul W Buehler
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

5.  First-pass accumulation of salicylic acid in gut tissue after absorption in anesthetized rat.

Authors:  Y M Choi; S M Chung; W L Chiou
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

6.  Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats.

Authors:  Anallely López-Yerena; Anna Vallverdú-Queralt; Raf Mols; Patrick Augustijns; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2020-02-05       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.